

L Number	Hits	Search Text	DB	Time stamp
-	19	camden.in. and quada.in. and agyin.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2004/03/25 11:36
-	131	camden.in. and vir\$4	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2004/03/25 11:42
-	19	quada.in. and vir\$4	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2004/03/25 11:42
-	19	agyin.in. and vir\$4	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2004/03/25 11:43
-	19	(quada.in. and vir\$4) or (agyin.in. and vir\$4)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2004/03/25 11:43
-	0	((quada.in. and vir\$4) or (agyin.in. and vir\$4)) not (camden.in. and quada.in. and agyin.in.)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2004/03/25 11:43
-	112	(camden.in. and vir\$4) not (camden.in. and quada.in. and agyin.in.)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2004/03/25 13:08
-	3	"6632809"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2004/03/25 13:10
-	9	"2034500"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2004/03/25 13:12
-	403	paget.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2004/03/25 13:12
-	0	paget.in. and sands.in	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2004/03/25 13:13
-	6	paget.in. and sands.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2004/03/25 13:45

-	3	"6482843"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2004/03/31 09:00
-	5	"6506783"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2004/03/31 09:01
-	8	"1254282"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2004/03/31 09:01
-	9	"763272"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2004/03/31 09:07
-	2	"9965870"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2004/03/31 09:10
-	3	"9851304"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2004/03/31 09:10

L4 ANSWER 1 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2004:57982 USPATFULL
TITLE: Gyrase inhibitors and uses thereof
INVENTOR(S): Grillot, Anne-Laure, Cambridge, MA, UNITED STATES
Charifson, Paul, Framingham, MA, UNITED STATES
Stamos, Dean, Framingham, MA, UNITED STATES
Liao, Yusheng, Lexington, MA, UNITED STATES
Badia, Michael, Bedford, MA, UNITED STATES
Trudeau, Martin, Tewksbury, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004043989	A1	20040304
APPLICATION INFO.:	US 2003-444588	A1	20030523 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-15332, filed on 12 Dec 2001, GRANTED, Pat. No. US 6632809		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256094P	20001215 (60)
	US 2001-275292P	20010313 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	VERTEX PHARMACEUTICALS INC., 130 WAVERLY STREET, CAMBRIDGE, MA, 02139-4242	

NUMBER OF CLAIMS: 56
EXEMPLARY CLAIM: 1
LINE COUNT: 2681
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds of the formula I: ##STR1##

or a pharmaceutically acceptable derivative or prodrug thereof. The compounds are useful as inhibitors of bacterial gyrase activity. The present invention also relates to methods for treating bacterial infections in mammals. The present invention also relates to methods for decreasing bacterial quantity in a biological sample.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2004:53416 USPATFULL
TITLE: Biaryl compounds as serine protease inhibitors
INVENTOR(S): Babu, Yarlagadda S., Birmingham, AL, United States
Rowland, R. Scott, Hoover, AL, United States
Chand, Pooran, Birmingham, AL, United States
Kotian, Pravin L., Birmingham, AL, United States
El-Kattan, Yahya, Hoover, AL, United States
Niwas, Shri, Birmingham, AL, United States
PATENT ASSIGNEE(S): BioCryst Pharmaceuticals, Inc., Birmingham, AL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6699994	B1	20040302
APPLICATION INFO.:	US 2002-127460		20020423 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US32582, filed on 22 Oct 2001		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-281735P	20010406 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	

PRIMARY EXAMINER: Kumar, Shailendra
LEGAL REPRESENTATIVE: Connolly Bove Lodge & Hutz LLP
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1,2
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 5004

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of formula (I) are useful as inhibitors of trypsin like serine protease enzymes such as thrombin, factor VIIa, factor Xa, TF/FVIIa, and trypsin. These compounds could be useful to treat and/or prevent clotting disorders, and as anticoagulating agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 17 CA COPYRIGHT 2004 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 139:261299 CA

TITLE: Preparation of broad spectrum substituted benzimidazolesulfonamide HIV protease inhibitors

INVENTOR(S): Surleraux, Dominique Louis Nestor Ghislain; Wigerinck, Piet Tom Bert Paul; Voets, Marieke Christiane Johanna; Vendeville, Sandrine Marie Helene; De Kock, Herman Augustinus; Vergouwen, Bernhard Joanna Bernard

PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd., Ire.

SOURCE: PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003076413	A1	20030918	WO 2003-EP50057	20030312
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: EP 2002-75999 A 20020312

OTHER SOURCE(S): MARPAT 139:261299

GI



AB Title compds. I [R1 = H, alkyl, alkenyl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, aryl, heterocyclic, heterocyclalkyl, aminoalkyl; R2 = H, alkyl; R3 = (un)substituted alkyl, aryl, cycloalkyl; R4 = H, (un)substituted CO2H, CONH2, cycloalkyl, alkenyl, alkynyl, OH, NH2; R5 = H, (un)substituted alkyl; R6 = H, (un)substituted alkyl, NH2; L = CO, CO2, (un)substituted NHCO, OXCO, NHXCO, SO2, SO3, NHSO2, NHXSO2, where either CO or SO2 is attached to NR2; X = alkanediyl] were prepared Thus, Me 2-benzimidazolecarbamate was chlorosulfonylated, treated with (1S,2R)-PhCH2CH(NHBoc)CH(OH)CH2NHCH2CHMe2, deblocked, and treated with 2,6-Me2C6H3OCH2CO2H to give the title compound II which had pIC50 against HIV-1 strain LAI of 8.5.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2003:174020 USPATFULL

TITLE: Gyrase inhibitors and uses thereof

INVENTOR(S): Grillot, Anne-Laure, Cambridge, MA, UNITED STATES
Charifson, Paul, Framingham, MA, UNITED STATES
Stamos, Dean, Framingham, MA, UNITED STATES
Liao, Yusheng, Lexington, MA, UNITED STATES
Badia, Michael, Bedford, MA, UNITED STATES
Tadeau, Martin, Tewksbury, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003119868	A1	20030626
	US 6632809	B2	20031014
APPLICATION INFO.:	US 2001-15332	A1	20011212 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256094P	20001215 (60)
	US 2001-275292P	20010313 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Tina M. Powers, VERTEX PHARMACEUTICALS INC., 130 Waverly Street, Cambridge, MA, 02139-4242

NUMBER OF CLAIMS: 56

EXEMPLARY CLAIM: 1

LINE COUNT: 2680

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds of the formula I: ##STR1##

or a pharmaceutically acceptable derivative or prodrug thereof. The compounds are useful as inhibitors of bacterial gyrase activity. The present invention also relates to methods for treating bacterial infections in mammals. The present invention also relates to methods for decreasing bacterial quantity in a biological sample.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2003:45352 USPATFULL
TITLE: Method of cancer treatment
INVENTOR(S): Camden, James Berger, West Chester, OH, UNITED STATES
PATENT ASSIGNEE(S): The Procter & Gamble Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003032664	A1	20030213
APPLICATION INFO.:	US 2002-198334	A1	20020718 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-374717, filed on 13 Aug 1999, GRANTED, Pat. No. US 6423734		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	THE PROCTER AND GAMBLE COMPANY, INTELLECTUAL PROPERTY DIVISION, WINTON HILL TECHNICAL CENTER - BOX 161, 6110 CENTER HILL AVENUE, CINCINNATI, OH, 45224		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
LINE COUNT:	959		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of treating and inhibiting cancer in animals by administering a therapeutically effective amount of a pharmaceutical composition having benzimidazole of the general formula: ##STR1##

wherein X is hydrogen, halogen, alkyl of less than 7 carbon atoms or alkoxy of less than 7 carbon atoms; n is a positive integer of less than 4; Y is hydrogen, chlorine, oxychloro, nitro, methyl or ethyl; and R is hydrogen, or an alkyl group of from 1 to 8 carbon atoms and R.sub.2 is NHCOOR.sub.1 wherein R.sub.1 is aliphatic hydrocarbon of less than 7 carbon atoms, and preferably an alkyl group of less than 7 carbon atoms and pharmaceutically acceptable derivatives alone, or in combination, or in conduction with other therapeutic agents such as other cancer inhibiting compounds, and operative combinations thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2003:13326 USPATFULL
TITLE: Cancer treatments and pharmaceutical compositions therefor
INVENTOR(S): Camden, James Berger, West Chester, OH, United States
PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6506783	B1	20030114
APPLICATION INFO.:	US 1997-857811		19970516 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Goldberg, Jerome D.		
LEGAL REPRESENTATIVE:	Hersko, Bart S.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		

NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)

LINE COUNT: 566

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition that inhibits the growth of tumors and cancers in mammals and can be used to treat **viral** infections that comprises a fungicide is disclosed. The particular fungicide used is a benzimidazole derivative having the formula:

##STR1##


wherein R is selected from the group consisting of H, carboxyl (--CO.sub.2H), hydroxyl, amino or esters (--CO.sub.2R') wherein R' is selected from the group consisting of alkoxy, haloalkyl, alkenyl, and cycloalkyl wherein the alkyl groups have from 1-8 carbons or CH.sub.3CH.sub.2(OCH.sub.2CH.sub.2).sub.n--or CH.sub.3CH.sub.2CH.sub.2(OCH.sub.2CH.sub.2CH.sub.2).sub.n--or (CH.sub.3).sub.2CH--(OCH(CH.sub.3)CH.sub.2).sub.n--wherein n is from 1-3, the pharmaceutically acceptable salts thereof, or mixtures thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 17 CA COPYRIGHT 2004 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 137:370090 CA
TITLE: Preparation of benzimidazolecarbamates for treatment of cancer or **viral** infections
INVENTOR(S): Quada, James C., Jr.; Agyin, Joseph K.; Camden, James Berger
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: U.S., 20 pp., Cont.-in-part of U.S. Ser. No. 857,811. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6482843	B1	20021119	US 2000-676407	20000929
US 6506783	B1	20030114	US 1997-857811	19970516
CN 1254282	A	20000524	CN 1997-182190	19971126
US 6077862	A	20000620	US 1999-259969	19990301
AU 763272	B2	20030717	AU 2001-37094	20010418
PRIORITY APPLN. INFO.:			US 1997-857811	A2 19970516
			AU 1998-74027	A3 19971126

OTHER SOURCE(S): MARPAT 137:370090
GI



AB Title compds., e.g. [I; R = O₂CR₁; R₁ = alkyl, haloalkyl, hydroxyalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkyl, (substituted) Ph, PhNH, PhCH₂, etc.], were prepared. Thus, Me 2-amino-5-hydroxybenzimidazole carbamate and 3,5,5-trimethylhexanoyl chloride were stirred in THF at 23-40° to give I (R = O₂CCH₂CHMeCH₂CMe₃). The latter inhibited human colon carcinoma with IC₅₀ = 15.8 μM.


REFERENCE COUNT: 106 THERE ARE 106 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 17 CA COPYRIGHT 2004 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 137:109276 CA
TITLE: Preparation of methyl 1H-benzimidazole-2-carbamates for treating cancer or **viral** infections
INVENTOR(S): Camden, James Berger; Agyin, Joseph K.; Quada, James C., Jr.
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: U.S., 19 pp., Cont. of U.S. Ser. No. 857,811., CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6423736	B1	20020723	US 2000-676409	20000929
US 6506783	B1	20030114	US 1997-857811	19970516
CN 1254282	A	20000524	CN 1997-182190	19971126
US 6077862	A	20000620	US 1999-259969	19990301
AU 763272	B2	20030717	AU 2001-37094	20010418

PRIORITY APPLN. INFO.: US 1997-857811 A2 19970516
AU 1998-74027 A3 19971126

OTHER SOURCE(S): MARPAT 137:109276
GI



AB The title compds. [I (R = OCOR_a; R_a = (un)substituted Ph), II (R = CONR₁R₂, CO₂R₁, OCOR₁, NHCOR₁; R₁ = alkyl, haloalkyl, cycloalkyl, etc.; R₂ = H, alkyl)] were prepared Thus, reacting Me 2-amino-5-hydroxybenzimidazolecarbamate with 3,5,5-trimethylhexanoyl chloride in THF afforded 57% I [R = OCOCH₂CHMeCH₂CMe₃] which showed IC₅₀ of 20.1 μM and IC₅₀ of 15.8 μM for growth inhibition of B16 murine melanoma cells and H29 human colon cancer cells, resp. Such compds. I may be used in combination with a chemotherapeutic agent and/or a potentiator.

REFERENCE COUNT: 119 THERE ARE 119 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 9 OF 17 CA COPYRIGHT 2004 ACS on STN DUPLICATE 4
ACCESSION NUMBER: 137:109275 CA
TITLE: Preparation of methyl 1H-benzimidazole-2-carbamates for treating cancer or **viral** infections
INVENTOR(S): Camden, James Berger; Quada, James C., Jr.; Agyin, Joseph K.
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: U.S., 17 pp., Cont. of U.S. Ser. No. 857,811., CODEN: USXXAM
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6423735	B1	20020723	US 2000-676029	20000929
US 6506783	B1	20030114	US 1997-857811	19970516
CN 1254282	A	20000524	CN 1997-182190	19971126
US 6077862	A	20000620	US 1999-259969	19990301
AU 763272	B2	20030717	AU 2001-37094	20010418

PRIORITY APPLN. INFO.: US 1997-857811 A2 19970516
AU 1998-74027 A3 19971126

OTHER SOURCE(S): MARPAT 137:109275
GI



I



II

AB The title compds. [I (R = OCORa; Ra = (un)substituted Ph), II (R = CONR1R2, CO2R1, OCOR1, NHCOR1; R1 = alkyl, haloalkyl, cycloalkyl, etc.; R2 = H, alkyl)] were prepared Thus, reacting Me 2-amino-5-hydroxybenzimidazolecarbamate with 3,5,5-trimethylhexanoyl chloride in THF afforded 57% I [R = OCOCH2CHMeCH2CMe3] which showed IC50 of 20.1 μ M and IC50 of 15.8 μ M for growth inhibition of B16 murine melanoma cells and H29 human colon cancer cells, resp. Such compds. I may be used in combination with a chemotherapeutic agent and/or a potentiator such as DNA-interactive agent, an antimetabolite, a tubulin-interactive agent, a hormonal agent, an antihormonal antigen, and an adrenal corticosteroid.

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 10 OF 17 CA COPYRIGHT 2004 ACS on STN DUPLICATE 5
ACCESSION NUMBER: 137:93753 CA
TITLE: Preparation of 2,5-disubstituted benzimidazoles used in the treatment of cancer or **viral** infections
INVENTOR(S): Camden, James Berger; Agyin, Joseph K.; Quada, James C., Jr.
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: U.S., 18 pp., Cont.-in-part of U. S. Ser. No. 857,811.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6420411	B1	20020716	US 2000-676202	20000929
US 6506783	B1	20030114	US 1997-857811	19970516
CN 1254282	A	20000524	CN 1997-182190	19971126
US 6077862	A	20000620	US 1999-259969	19990301
AU 763272	B2	20030717	AU 2001-37094	20010418

PRIORITY APPLN. INFO.: US 1997-857811 A2 19970516
AU 1998-74027 A3 19971126

OTHER SOURCE(S): MARPAT 137:93753

GI




AB Title compds. I [R1 = (halo)alkyl, hydroxyalkyl, (halo)alkenyl, cycloalkyl, heterocycloalkyl, substituted Ph and analogs thereof] were prepared For instance, Me 5-amino-1H-benzimidazol-2-ylcarbamate was acylated with 3,5,5-trimethylhexanoyl chloride to provide I (R1 = CH2CH(CH3)CH2C(CH3)3; II). II had IC50 = 6.6 and 7.0 μ M for the murine melanoma and human colon carcinoma cell line resp. I are used for the treatment of cancers or **viral** infections and may be used in combination with a chemotherapeutic agent and/or a potentiator.

REFERENCE COUNT: 115 THERE ARE 115 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 17 CA COPYRIGHT 2004 ACS on STN DUPLICATE 6
 ACCESSION NUMBER: 137:33301 CA
 TITLE: Preparation of 2,5-disubstituted benzimidazoles used in the treatment of cancer or **viral** infections
 INVENTOR(S): Quada, James C., Jr.; Agyin, Joseph K.; Camden, James Berger
 PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
 SOURCE: U.S., 18 pp., Cont.-in-part of U.S. Ser. No. 857,811. CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6407131	B1	20020618	US 2000-676030	20000929
US 6506783	B1	20030114	US 1997-857811	19970516
CN 1254282	A	20000524	CN 1997-182190	19971126
US 6077862	A	20000620	US 1999-259969	19990301
AU 763272	B2	20030717	AU 2001-37094	20010418
PRIORITY APPLN. INFO.:			US 1997-857811	A2 19970516
			AU 1998-74027	A3 19971126

OTHER SOURCE(S): MARPAT 137:33301
 GI



AB Title compds. I [R1 = (halo)alkyl, hydroxyalkyl, (halo)alkenyl, cycloalkyl, heterocycloalkyl, substituted Ph and analogs thereof] were prepared For instance, Me 2-amino-5-hydroxybenzimidazole carbamate was

acylated with 3,5,5-trimethylhexanoyl chloride to provide I (R1 = CH₂CH₂CH(CH₃)CH₂C(CH₃)₃; II). II had IC₅₀ = 20.1 and 15.8 µM for the murine melanoma and human colon carcinoma cell line resp. I are used for the treatment of cancers or **viral** infections and may be used in combination with a chemotherapeutic agent and/or a potentiator.

REFERENCE COUNT: 115 THERE ARE 115 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2002:92677 USPATFULL
TITLE: Sulfonamide inhibitors of aspartyl protease
INVENTOR(S): Hale, Michael Robin, Bedford, MA, UNITED STATES
Andrews, Clarence Webster, III, Durham, NC, UNITED STATES
Furfine, Eric Steven, Durham, NC, UNITED STATES
Sherrill, Ronald George, Cary, NC, UNITED STATES
Spaltenstein, Andrew, Raleigh, NC, UNITED STATES
Lowen, Gregory Thomas, Williamsburg, VA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002049201	A1	20020425
	US 6613743	B2	20030902
APPLICATION INFO.:	US 2000-731129	A1	20001206 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1999-US13744, filed on 17 Jun 1999, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-90094P	19980619 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & NEAVE, 1251 AVENUE OF THE AMERICAS, 50TH FLOOR, NEW YORK, NY, 10020-1105	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	7574	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-**viral** agents against the HIV-1 and HIV-2 **viruses**. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2002:181706 USPATFULL
TITLE: Method of preventing cancer
INVENTOR(S): Camden, James Berger, West Chester, OH, United States
PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6423734	B1	20020723

APPLICATION INFO.: US 1999-374717 19990813 (9)
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Goldberg, Jerome D.
LEGAL REPRESENTATIVE: Hersko, Bart S.
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1090

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of treating and inhibiting cancerin animals by administering a therapeutically effective amount of a pharmaceutical composition having benzimidazole of the general formula: ##STR1##

wherein X is hydrogen, halogen, alkyl of less than 7 carbon atoms or alkoxy of less than 7 carbon atoms; n is a positive integer of less than 4; Y is hydrogen, chlorine, oxychloro, nitro, methyl or ethyl; and R is hydrogen, or an alkyl group of from 1 to 8 carbon atoms and R.sub.2 is NHCOOR.sub.1 wherein R.sub.1 is aliphatic hydrocarbon of less than 7 carbon atoms, and preferably an alkyl group of less than 7 carbon atoms and pharmaceutically acceptable derivatives alone, or in combination, or in conduction with other therapeutic agents such as other cancer inhibiting compounds, and operative combinations thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2000:143079 USPATFULL

TITLE: Printer using print cartridge with internal pressure regulator

INVENTOR(S): Pawlowski, Jr., Norman E., Corvallis, OR, United States
Hauck, Mark, Corvallis, OR, United States
Barinaga, John A., Corvallis, OR, United States
PATENT ASSIGNEE(S): Hewlett-Packard Company, Palo Alto, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6137513		20001024
APPLICATION INFO.:	US 1998-90094		19980603 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-550902, filed on 31 Oct 1995, now patented, Pat. No. US 5872584 which is a continuation-in-part of Ser. No. US 1995-518847, filed on 24 Aug 1995, now patented, Pat. No. US 5736992 which is a continuation-in-part of Ser. No. US 1994-331453, filed on 31 Oct 1994, now patented, Pat. No. US 5583545 And a continuation-in-part of Ser. No. US 1995-429915, filed on 27 Apr 1995, now patented, Pat. No. US 5825387 And a continuation-in-part of Ser. No. US 1995-566821, filed on 4 Dec 1995, now patented, Pat. No. US 5777646		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Le, N.
ASSISTANT EXAMINER: Vo, Anh T. N.
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 11
NUMBER OF DRAWINGS: 69 Drawing Figure(s); 48 Drawing Page(s)
LINE COUNT: 1718

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In the preferred embodiment, an inkjet printer includes a replaceable print cartridge which is inserted into a scanning carriage. An ink tube extends from the scanning carriage to a separate ink supply located within the printer. A fluid interconnect on the print cartridge connects

to a fluid interconnect on the carriage when the print cartridge is inserted into the carriage to complete the fluid connection between the external ink supply and the print cartridge. In one embodiment, the fluid interconnection is made between the print cartridge and the ink tube simply by placing the print cartridge into a stall in the scanning carriage. A pressure regulator internal to the print cartridge regulates the flow of ink from the external ink supply to the print cartridge. The external ink supply may be pressurized or non-pressurized.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 15 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2000:77377 USPATFULL
TITLE: **Virus** and cancer treatments
INVENTOR(S): Camden, James Berger, West Chester, OH, United States
PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6077862		20000620
APPLICATION INFO.:	US 1999-259969		19990301 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-857811, filed on 16 May 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Goldberg, Jerome D.		
LEGAL REPRESENTATIVE:	Dabek, Rose Ann, Rasser, J. C.		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
LINE COUNT:	549		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition that inhibits the growth of tumors and cancers in mammals and can be used to treat **viral** infections that comprises a fungicide is disclosed. The particular fungicide used is a benzimidazole derivative having the formula: ##STR1## wherein R is selected from the group consisting of H, carboxyl (--CO.sub.2 H), hydroxyl, amino or esters (--CO.sub.2 R') wherein R' is selected from the group consisting of alkoxy, haloalkyl, alkenyl, and cycloalkyl wherein the alkyl groups have from 1-8 carbons or CH.sub.3 CH.sub.2 (OCH.sub.2 CH.sub.2).sub.n --or CH.sub.3 CH.sub.2 CH.sub.2 (OCH.sub.2 CH.sub.2).sub.n --or (CH.sub.3).sub.2 CH-- (OCH(CH.sub.3)CH.sub.2).sub.n -- wherein n is from 1-3, the pharmaceutically acceptable salts thereof, or mixtures thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 16 OF 17 CA COPYRIGHT 2004 ACS on STN DUPLICATE 7
ACCESSION NUMBER: 132:49801 CA
TITLE: Preparation of 1-acylamino-3-(N-arylsulfonyl-N-alkoxyamino)-2-hydroxypropanes and related compounds as inhibitors of HIV aspartyl protease.
INVENTOR(S): Sherrill, Ronald George; Hale, Michael R.; Spaltenstein, Andrew; Furfine, Eric Steven; Andrews, Clarence Webster, III; Lowen, Gregory Thomas
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
SOURCE: PCT Int. Appl., 344 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 9965870	A2	19991223	WO 1999-US13744	19990617
WO 9965870	A3	20010315		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2335477	AA	19991223	CA 1999-2335477	19990617
AU 9945760	A1	20000105	AU 1999-45760	19990617
AU 767728	B2	20031120		
EP 1086076	A1	20010328	EP 1999-928769	19990617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9912169	A	20010410	BR 1999-12169	19990617
NZ 508855	A	20031031	NZ 1999-508855	19990617
US 2002049201	A1	20020425	US 2000-731129	20001206
US 6613743	B2	20030902		
NO 2000006405	A	20010219	NO 2000-6405	20001215
PRIORITY APPLN. INFO.:			US 1998-90094P	P 19980619
			WO 1999-US13744	W 19990617

OTHER SOURCE(S): MARPAT 132:49801

AB ABxN(Gx)CHDCHOR7CH2ND'SO2E [A = H, (substituted) Ht, R1Ht, R1Ak; Ak = alkyl; Ht = cycloalkyl, cycloalkenyl, (substituted) aryl, heterocyclyl; R1 = CO, SO2, COCO, O2C, NR2CO, NR2SO2, etc.; B = null, NR2C(R3)2CO; x = 0, 1; R2 = H, (substituted) Ht, alkyl; R3 = H, (substituted) Ht, alkyl, alkenyl, cycloalkyl, cycloalkenyl; G = null, H, R7, alkyl; G may be bound to R7; D = (substituted) Q, alkyl, alkenyl; Q = (substituted) carbocyclyl, heterocyclyl; D' = OR10, N:R10, N(R10)R1R3; E = Ht, OHt, OR3, NR2R3, (substituted) alkyl, alkenyl, etc.; R7 = H, (CH2O)xY(ZM)(:X)Z(M)x, etc.; M = null, H, Li, Na, K, Mg, Ca, Ba, alkyl, alkenyl, etc.; X = O, S; Y = P, S; Z = O, S, N(R2)2, H], were prepared as inhibitors of HIV aspartyl protease (no data). Thus, 3-H2NC6H4SO2NHOCHMe2 (preparation given), tert-Bu N-(1S)-1-[(2S)-oxiran-2-yl]-2-phenylethylcarbamate, and phosphazene base P4 tert-Bu were stirred in 8 h in THF to give 95% tert-Bu N-(1S,2R)-3-[[3-aminophenyl)sulfonyl](isopropoxy)amino]-1-benzyl-2-hydroxypropylcarbamate.

L4 ANSWER 17 OF 17 CA COPYRIGHT 2004 ACS on STN DUPLICATE 8

ACCESSION NUMBER: 130:20597 CA

TITLE: Benzimidazole-2-carbamates for the treatment of viral infections and cancer

INVENTOR(S): Camden, James Berger

PATENT ASSIGNEE(S): The Procter & Gamble Company, USA

SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9851304	A1	19981119	WO 1997-US21565	19971126
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,				

GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
GN, ML, MR, NE, SN, TD, TG

US 6506783	B1	20030114	US 1997-857811	19970516
AU 9874027	A1	19981208	AU 1998-74027	19971126
AU 728690	B2	20010118		
EP 956017	A1	19991117	EP 1997-949600	19971126

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI


BR 9714634	A	20000523	BR 1997-14634	19971126
CN 1254282	A	20000524	CN 1997-182190	19971126
NZ 335159	A	20010928	NZ 1997-335159	19971126
JP 2001527523	T2	20011225	JP 1998-521930	19971126
US 6077862	A	20000620	US 1999-259969	19990301
AU 763272	B2	20030717	AU 2001-37094	20010418

PRIORITY APPLN. INFO.:

US 1997-857811	A	19970516
AU 1998-74027	A3	19971126
WO 1997-US21565	W	19971126

OTHER SOURCE(S): MARPAT 130:20597

GI



AB A pharmaceutical composition that is effective in the treatment of HIV and other **viral** infections and inhibits growth of cancers and tumors in mammals comprises a benzimidazole derivative (I; R = H, CO₂H, OH, NH₂, CO₂R₁; R₁ = alkoxy, haloalkyl, alkenyl, cycloalkyl), the pharmaceutically acceptable salts thereof, or mixts. thereof. I (R = H) inhibits the growth of B16 murine melanoma and HT29 human colon carcinoma cells with IC₅₀ of 4.925 and 3.297 μ M, resp.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT